| Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer KT Flaherty, PM LoRusso, A DeMichele, VG Abramson, R Courtney, ... Clinical Cancer Research 18 (2), 568-576, 2012 | 384 | 2012 |
| Drug efflux transporters in the CNS H Sun, H Dai, N Shaik, WF Elmquist Advanced drug delivery reviews 55 (1), 83-105, 2003 | 382 | 2003 |
| Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. JP Leonard, AS Lacasce, MR Smith, A Noy, LR Chirieac, SJ Rodig, JQ Yu, ... Blood, 2012 | 344 | 2012 |
| Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) GK Schwartz, PM LoRusso, MA Dickson, SS Randolph, MN Shaik, ... British journal of cancer 104 (12), 1862-1868, 2011 | 308 | 2011 |
| P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib Y Chen, S Agarwal, NM Shaik, C Chen, Z Yang, WF Elmquist Journal of Pharmacology and Experimental Therapeutics 330 (3), 956-963, 2009 | 244 | 2009 |
| P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution N Shaik, N Giri, G Pan, WF Elmquist Drug metabolism and disposition 35 (11), 2076-2085, 2007 | 105 | 2007 |
| Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design N Giri, S Agarwal, N Shaik, G Pan, Y Chen, WF Elmquist Drug Metabolism and Disposition 37 (3), 560-570, 2009 | 95 | 2009 |
| Lenacapavir: a first-in-class HIV-1 capsid inhibitor H Dvory-Sobol, N Shaik, C Callebaut, MS Rhee Current Opinion in HIV and AIDS 17 (1), 15-21, 2022 | 87 | 2022 |
| Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse N Giri, N Shaik, G Pan, T Terasaki, C Mukai, S Kitagaki, N Miyakoshi, ... Drug Metabolism and Disposition 36 (8), 1476-1484, 2008 | 84 | 2008 |
| Interactions of pluronic block copolymers on P‐gp efflux activity: Experience with HIV‐1 protease inhibitors N Shaik, G Pan, WF Elmquist Journal of pharmaceutical sciences 97 (12), 5421-5433, 2008 | 71 | 2008 |
| Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies C Jamieson, JE Cortes, V Oehler, M Baccarani, HM Kantarjian, ... Blood 118 (21), 424, 2011 | 65 | 2011 |
| Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials JE Cortes, H Dombret, A Merchant, T Tauchi, CG DiRienzo, B Sleight, ... Future Oncology 15 (31), 3531-3545, 2019 | 51 | 2019 |
| Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies N Shaik, N Giri, WF Elmquist Journal of pharmaceutical sciences 98 (11), 4170-4190, 2009 | 35 | 2009 |
| Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib AT Gerds, T Tauchi, E Ritchie, M Deininger, C Jamieson, R Mesa, ... Leukemia research 79, 38-44, 2019 | 28 | 2019 |
| Phase I Study of PD 0332991, a Novel, Oral, Cyclin-D Kinase (CDK) 4/6 Inhibitor in Combination with Letrozole, for First-Line Treatment of Metastatic Post-Menopausal, Estrogen … R Finn, S Hurvitz, M Allison, S Applebaum, J Glaspy, B DiCarlo, ... Cancer Research 69 (24_Supplement), 5069-5069, 2009 | 21 | 2009 |
| Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study N Shaik, B Hee, H Wei, RR LaBadie Cancer Chemotherapy and Pharmacology 83, 463-472, 2019 | 17 | 2019 |
| A phase I study of PD 0332991: complete CDK4/6 inhibition and tumor response in sequential combination with bortezomib and dexamethasone for relapsed and refractory multiple … R Niesvizky, S Lentzsch, AZ Badros, AA Chanan-Khan, SB Singhal, ... Program and abstracts of the 52nd Annual Meeting of the American Society of …, 2010 | 17 | 2010 |
| Population pharmacokinetics of glasdegib in patients with advanced hematologic malignancies and solid tumors S Lin, N Shaik, G Martinelli, AJ Wagner, J Cortes, A Ruiz‐Garcia The Journal of Clinical Pharmacology 60 (5), 605-616, 2020 | 13 | 2020 |
| Absolute oral bioavailability of glasdegib (PF‐04449913), a smoothened inhibitor, in randomized healthy volunteers N Shaik, B Hee, Y Liang, RR LaBadie Clinical Pharmacology in Drug Development 8 (7), 895-902, 2019 | 11 | 2019 |
| 588 A First-in-patient Phase I Study of the Novel Gamma Secretase Inhibitor PF-03084014 in Patients with Advanced Solid Tumor Malignancies WA Messersmith, PM LoRusso, JM Cleary, A Dasari, B Huang, NM Shaik, ... European Journal of Cancer, 180, 2012 | 8 | 2012 |
